Unlicensed Cannabis Products in New York Contaminated with Harmful Substances

Dec.02.2022
Unlicensed Cannabis Products in New York Contaminated with Harmful Substances
An industry report found illegal marijuana sales in New York contain harmful bacteria, heavy metals, and toxic pesticides.

A report released on Wednesday reveals that some marijuana products sold in unlicensed stores in New York are not only illegal but contaminated with harmful bacteria, heavy metals, and toxic pesticides.


The association conducted laboratory tests on smokable cannabis, edible candies, and vaporizers purchased from 20 tobacco shops and pharmacies. They found eight different contaminants, including E. coli, salmonella, nickel, and lead, which are prohibited. According to a report from the New York Medical Marijuana Industry Association, a state trade organization, the investigation also revealed that some products had incorrect labeling of their strength.


The association represents licensed healthcare pharmacy operators in New York. It stated that the investigation's results highlight the concerns of elected officials and regulatory agencies regarding the danger posed by the reckless growth of retail stores in the state, which falsely claim that their products are legal.


At present, legal sales of marijuana in New York are limited to patients of 38 medical dispensaries operated by the association. However, prior to the release of this report, regulatory authorities granted licenses to 36 retail dispensaries in the state's first batch of approvals. The regulatory authorities stated that legal sales of recreational marijuana will begin in December.


The industry association stated in its report that "just as the imperial government was preparing to achieve this important goal, new illegal operators have emerged, seizing the tail of the highly respected legacy market, endangering public health and safety as well as the long-term success of legitimate operators.


For years, medical pharmacy operators have been frustrated by their exclusion from the New York retail market due to the prevalence of unlawful storefronts operating without regulation or repercussions. The report aims to pressure authorities to restrict illegal sales, as the healthcare industry seeks modifications to proposed regulations that would require them to pay at least $3 million to enter the retail market.


According to laboratory results, these tests were authorized by Curaleaf, a national chain with four locations in New York, currently facing fines, lawsuits, and product recalls in at least five states as well as license revocations in Oregon.


In Kura Sushi's statement, it defended the reputation of the company by pointing out that the suspension in Oregon is the first time in the 12 years of operation of the chain. A senior female spokesperson stated that this incident involves mislabeled products, and the discovery proves that supervision of the industry is working and regulatory agencies are also taking note of the company's cooperation.


She said that illegal markets in New York or any other state do not have this type of regulatory mechanism.


A newspaper has obtained a report from a basic laboratory test, but no independent verification of any testing results has been completed. Experts advise caution when interpreting these findings, noting that bacteria die when exposed to smoke and some metals and pesticides are considered safe in low amounts. Officials from the city government and cannabis regulatory agencies have stated that they are reviewing the report.


Overall, tests revealed that 16 out of 40 products were found to contain pollutants. Nine products contained tetrahydrocannabinol (THC), the intoxicating compound found in marijuana, at levels lower than what was advertised on their labels. However, analysis showed that one type of gummy candy claimed to have 100 milligrams of THC per piece on its label, but actually contained twice that amount.


The most common pollutants found in cannabis products are Escherichia coli and Salmonella, which were detected in nine different items, particularly loose bud and pre-rolled joints. National regulations prohibit the sale of cannabis products contaminated with these bacteria to consumers. Both types of bacteria can cause infections, often resulting in symptoms such as diarrhea, vomiting, fever, and cramps. In severe cases, they can be life-threatening.


The CEO of Talon Analytical, a laboratory licensed by the state, Michael Bianco, has stated that the tested products do not meet the standards set in New York. The company has tested illegal products for their clients, which are mostly medical marijuana companies.


The spokesperson for the Cannabis Control Office, Aaron Ghitelman, stated that the report confirms officials' long-standing claims about the risks of unregulated products and the necessity of shutting down unlicensed storefronts. The agency's governing board passed regulation last week denying licenses to individuals who sell marijuana in unlicensed storefronts or vehicles, or in any other way falsely claiming to be operating legally.


The office is currently involved in a cross-departmental joint law enforcement pilot with the city. Mayor Eric Adams has stated that this initiative has resulted in the confiscation of over 100,000 items and the issuance of 300 civil and criminal violations.


Officials did not indicate whether they will take action against any specific companies that were involved in the sale of tested products mentioned in the report.


2FIRSTS will continue to provide updates on this issue, with further information available on the '2FIRSTS APP'. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
A 12-week European Commission consultation on revising the Tobacco Products Directive and Tobacco Advertising Directive is due to close on Aug. 14, 2026. The Commission has identified e-cigarette flavours, disposable vapes, tobacco heating devices, nicotine pouches, nicotine-free e-cigarettes, packaging and digital marketing among areas for possible new EU rules. National regulations already vary significantly across the bloc, a fragmentation the Commission says creates internal-market barriers and distorts competition. No formal revised TPD/TAD legislative text has yet been published, with the Commission currently indicating December 2026 for the legislative initiative.
Aug.14
UK Vape Brands Face White-Packaging and Flavour-Name Curbs in Youth-Appeal Crackdown
UK Vape Brands Face White-Packaging and Flavour-Name Curbs in Youth-Appeal Crackdown
The UK government and devolved administrations have launched a 12-week consultation on proposals to make vapes less appealing to children, including plain white packaging, limits on device colours, restrictions on flavour names and changes to how products are displayed in shops.
Jul.10
U.S. Appeals Court Says BAT Must Face Class Action Over Cigarette Labels
U.S. Appeals Court Says BAT Must Face Class Action Over Cigarette Labels
A U.S. appeals court ruled that British American Tobacco (BAT) must continue facing a consumer class action lawsuit over cigarette labels. The ruling allows the case to proceed but does not determine that BAT violated the law or is liable for damages. The case highlights ongoing legal risks facing major tobacco companies related to product labeling, consumer disclosures and product liability claims.
Jul.31
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Japan Health Ministry Cites Limited Evidence in Decision Not to Tighten Heated Tobacco Rules
Japan Health Ministry Cites Limited Evidence in Decision Not to Tighten Heated Tobacco Rules
Japan’s health ministry has proposed not tightening regulations on heated tobacco products to the same level as cigarettes as part of a review of passive smoking measures, with an expert panel broadly agreeing with the proposal, Jiji Press reported.
Jul.10
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28